ORTEXORTEX News
Tracking IBKR? Get live short interest, options flow, and signals on ORTEX.Sign up free →
IB
ConfluenceIBKR

IBKR Options Hedging Jumps as Insiders Sold Ahead of Rally

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 22 Jun 2026, 06:04

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Options traders are paying up to hedge IBKR despite — or because of — an 11.5% monthly rally. The put-call ratio hit 0.668 on June 18, sitting 2.1 standard deviations above its 20-day mean of 0.623. That's the loudest options signal in recent weeks for the brokerage group.

Executives Cashed Out Near the Lows

The more striking backdrop is what insiders did in early May. On May 8, a cluster of senior executives sold simultaneously. CEO Milan Galik sold 255,039 shares at $84.42 — worth $21.5 million. CFO Paul Brody sold 82,920 shares for $7.0 million. The CIO and Executive Vice Chairman each sold over $1.8 million worth on the same day. Combined, insiders net sold over $36 million in the past 90 days. The stock has since climbed to $96, so those sales look early rather than prescient — but the scale is notable with July 14 earnings approaching.

Shorts Have Built, Not Fled

Short interest stands at 2.9% of free float, up roughly 21% over the past month. That's a meaningful build in absolute terms, though the level remains low. With availability at 6,717% — more than 258 million shares sitting in the lending pool — there is no squeeze pressure. Cost to borrow is just 0.33%, near the floor. Shorts are not under stress. They are adding deliberately, likely as a pre-earnings hedge.

Analyst Targets Already Exceeded

Wall Street lifted targets aggressively in late April. Goldman Sachs raised to $98. BMO Capital and Barclays each went to $93. The stock now trades at $96 — above or at every major target set after the last earnings report. The consensus remains "buy," but the upside case has narrowed as the price has run.

What Converges Here

Three signals align ahead of July 14 earnings:

  • Options: PCR at 2.1 sigma above the 20-day mean — elevated put demand relative to calls
  • Short interest: Up 21% month-on-month, though borrow remains plentiful
  • Insider selling: $36M+ net sold in the 90 days to June 1, by CEO, CFO, CIO, and Vice Chairman simultaneously

The lending market itself is quiet. This is not a short-squeeze setup. It is an earnings-positioning story — with shorts and put buyers both pressing against a stock that has outrun its analyst targets on strong momentum.


Data summary

  • Price: $96.00 (+11.5% month, +8.1% week)
  • SI % of free float: 2.91% (+20.8% month)
  • Availability: 6,717% (extremely loose)
  • Cost to borrow: 0.33%
  • PCR: 0.668 (z-score +2.1 vs 20-day mean)
  • Next earnings: July 14, 2026
  • Insider net sold (90d): ~$36M

Stocks in this article

See the live data behind this article on ORTEX.

Open IBKR on ORTEX →

How this article was generated

Generated
22 Jun 2026, 06:07
Data as of
22 Jun 2026, 06:04
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notes

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.